angiotensin II-induced calcium signaling in striatal neurons Rafael Rivas-Santisteban , Ana Muñoz , Jaume Lillo , Iu Raïch , Ana Rodríguez-Pérez , Gemma Navarro , José Labandeira-García , Rafael Franco Endomembrane

Breakthroughs this week: Eli Lilly cuts Zepbound prices; GNAI1 missense mutation study; rapid Gαs endosomal translocation. 🔍 This Week in Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly

include: Abalone Bio · AbbVie · Biagon · Biolexis Therapeutics · Confo Therapeutics · Eli Lilly day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly

After 7 years at WL/PD and 26 years at Eli Lilly & Co., he retired at the end of 2014 and since then has been writing papers on his final major project at Lilly, a dopamine D1 PAM series that has advanced In 1988, he joined Lilly as a receptor biologist in charge of a high-throughput screening lab.

Martin Marro, currently Executive Director and Head of Cell Pharmacology at Eli Lilly’s Obesity Research Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic Area at Lilly's

of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's